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Based on single agent activities and the additive or synergistic effects of three individual drugs in gastric cancer, we performed a phase
II study of a new regimen combining epirubicin, docetaxel and cisplatin (EDP) for unresectable gastric cancer. The patients with
histologically confirmed metastatic or recurrent, unresectable gastric cancer and no history of palliative chemotherapy were eligible
for this trial. In total, 40mgm
 2 epirubicin (reduced to 30mgm
 2 due to high incidence of febrile neutropaenia; 75%) intravenously
(i.v.) over 30min, followed by 60mgm
 2 docetaxel i.v. over 1h, then 75mgm
 2 cisplatin i.v. over 1h was administered every 3
weeks. Between January 2002 and February 2003, 30 patients (epirubicin 40mgm
 2, eight; 30mgm
 2, 22) were enrolled. The
median age was 52 years (range, 33–68). The patients received a median of four cycles (range, 1–8). One patient (3%) achieved a
complete response, 13 (43%) showed partial responses, 13 (43%) had stable diseases and three (10%) progressed. The overall
response rate was 47% (95% CI, 28–66%), and the median duration of response was 5.0 months (95% CI, 3.0–7.0). The median
time to progression was 4.1 months (95% CI, 2.4–5.9), and the median overall survival was 11.0 months (95% CI, 9.5–12.4). Grade 4
neutropaenia were observed in 41%, and febrile neutropaenia in 32%, out of the patients receiving 30mgm
 2 of epirubicin. Grade 3
nonhaematological toxicities included nausea, vomiting, anorexia and peripheral neuropathy. In conclusion, EDP is active in gastric
cancer, with a manageable and predictable toxicity profile.
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Gastric cancer is the most common malignancy in Korea (Bae et al,
2002). The prognosis of unresectable gastric cancer has been
improved by cytotoxic chemotherapy, but median survival rarely
exceeds 1 year (Pyrhonen et al, 1995; Glimelius et al, 1997; Webb
et al, 1997; Ohtsu et al, 2003).
Single agents such as doxorubicin, cisplatin, 5-fluorouracil (5-
FU) and mitomycin-C have modest activities, showing response
rates of about 20% against gastric cancer. The median duration of
response is usually between 3 and 4 months, and occasional
complete responses (CRs) have been noted (Moertel and Lavin,
1979; Cocconi et al, 1982; Aabo et al, 1985).
Many combinations of cytotoxic chemotherapeutic agents have
been developed to improve the remission rate and duration of
survival. In the late 1980s and early 1990s, FAM (5-FU,
doxorubicin, mitomycin-C), FP (5-FU, cisplatin), FAMTX (5-FU,
doxorubicin, methotrexate), EAP (etoposide, doxorubicin, cispla-
tin) and ECF (epirubicin, cisplatin, protracted 5-FU) showed high
response rates in phase II trials, but lower response rates and
overall survival (OS) of less than 1 year in randomised trials (Wilke
and Cutsem, 2003). Randomised trials showed FAMTX was
superior to FAM (in efficacy) and EAP (in safety), and ECF was
superior to FAMTX in terms of response rate and survival (Wils
et al, 1991; Kelsen et al, 1992; Webb et al, 1997). However, the
median survival of the ECF regimen ranged from 8 to 10 months in
the phase III trials (Webb et al, 1997; Ross et al, 2002).
New agents such as taxane, irinotecan and oxaliplatin combined
with old agents such as cisplatin and 5-fluorouracil are currently
under evaluation to further improve treatment outcome (Wilke
and Cutsem, 2003). Docetaxel as a single agent showed response
rates of 17–24% (Sulkes et al, 1994; Einzig et al, 1996), and the
combination of docetaxel and cisplatin has shown a response rate
of 37–56% and OS of 9–10.4 months (Roth et al, 2000; Ridwelski
et al, 2001).
Although the combination of docetaxel and anthracycline has
not been studied enough in gastric cancer, the synergism between
docetaxel and anthracycline is well established in other cancers,
especially breast cancer (Pagani et al, 2000). Compared with
doxorubicin, epirubicin has the advantages of less cardiotoxicity
and less myelosuppression, with similar cytotoxic effect (Cersosi-
mo and Hong, 1986; Vorobiof and Falkson, 1989). A combination
of epirubicin and docetaxel showed a response rate of 22% and
progression-free survival of 16 weeks when used as a second-line
treatment in advanced gastric cancer (Andre et al, 1999). In
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laddition, epirubicin has proven to have synergistic clinical effect
with cisplatin (Kyoto Research Group for Chemotherapy of Gastric
Cancer, 1992) in gastric cancer.
Combination chemotherapy with 40mgm
 2 of epirubicin,
75mgm
 2 of docetaxel and 75mgm
 2 of cisplatin were adminis-
tered in transitional cell carcinoma (Pectasides et al, 2000). The
study reported tolerable toxicity profiles, but 53% of the patients
were required at least one dose reduction due to haematological
toxicities. According to the findings of the study, we planned to
administer 60mgm
 2 of docetaxel instead of 75mgm
 2 in
combination with the other two drugs.
Based on the single agent activities of epirubicin, docetaxel and
cisplatin (EDP), and the additive or synergistic clinical effects of
these three drugs in gastric cancer, we performed a phase II trial of
combination chemotherapy with EDP for patients with metastatic
or recurrent, unresectable gastric cancer.
MATERIALS AND METHODS
This was an open-label, single institution, phase II study of
combination therapy with EDP in metastatic or recurrent,
unresectable gastric cancer. Patients were enrolled at Samsung
Medical Center between January 2002 and February 2003. The
study was approved by the institutional review board, and written
informed consent was obtained from each patient.
Patient eligibility
Patients with histologically confirmed metastatic or recurrent,
unresectable gastric adenocarcinoma were eligible for this study.
Actually all patients had metastatic gastric adenocarcinoma, with
or without history of surgery with curative intent. All patients were
required to be between 18 and 70 years, to have an Eastern
Cooperative Oncology Group (ECOG) performance status (PS) of
0–2, and to have bidimensionally measurable disease (defined as
the presence of at least one index lesion capable of two-
dimensional measurement by computed tomography scan or chest
X-ray above 2cm in greatest diameter). Any history of chemother-
apy for palliation was not allowed, but adjuvant chemotherapy
elapsing more than 12 months previously was allowed. Other
eligibility criteria included an absolute neutrophil count (ANC)
X1500mm
 3, a platelet count X100000mm
 3, serum aspartate
aminotransferase (AST) and alanine aminotransferase (ALT)
activities p3.0 times the upper normal limit (UNL) (in cases of
liver metastasis, AST and ALT p5.0 UNL), serum bilirubin level
p1.25 times UNL, creatinine clearance (Cockroft formula)
X60mlmin
 1 and left ventricular ejection fraction X50%.
Patients with metastasis to the central nervous system were
excluded from the study. Prior history of another malignancy
within 5 years of study entry, apart from basal cell carcinoma of
the skin or carcinoma in situ of the uterine cervix, or grade 2–4
peripheral neuropathy, precluded participation in the current trial.
Patients with clinically significant cardiac disease as defined by
symptomatic ventricular arrhythmias, history of congestive heart
failure, or history of previous myocardial infarction within 12
months of study entry were also excluded.
Study protocol
Patients received 40mgm
 2 (reduced to 30mgm
 2 due to
unexpectedly high incidence of febrile neutropaenia; 75%) of
epirubicin intravenously (i.v.) over 30min, followed by 60mgm
 2
of docetaxel i.v. over 1h, and then followed by 75mgm
 2 of
cisplatin i.v. over 1h on day 1. Cycles were repeated every 3 weeks.
Dexamethasone premedication was used for prophylaxis of
docetaxel-induced hypersensitivity and fluid retention. Adequate
hydration and intravenous mannitol were used for the prophylaxis
of cisplatin-induced nephrotoxicity. Half saline 1000ml plus KCl
20mEq was administered intravenously over 2h each before and
after cisplatin. Patients were discontinued from the study therapy
when there was evidence of disease progression, the patient
experienced unacceptable toxicity, the patient requested disconti-
nuation, or the investigator decided that the patient should be
withdrawn.
The primary end point of the trial was response rate. The
secondary end points were duration of response, time to
progression (TTP), OS and toxicity.
Dose modification
Chemotherapy was withheld if the ANC was o1500mm
 3 or the
platelet count was o100000mm
 3 on day 1. In this case, the
complete blood cell count was repeated at least weekly and
chemotherapy was restarted as soon as the ANC reached
X1500mm
 3 and platelet count X100000mm
 3. If nadir ANC
was less than 500mm
 3 or the nadir platelet count was less than
50000mm
 3, the doses of epirubicin and docetaxel were reduced
to 30 and 45mgm
 2, respectively, and in the patients who received
30mgm
 2 of epirubicin, docetaxel alone was reduced to
45mgm
 2. If the calculated creatinine clearance (Ccr) was less
than 50mlmin
 1, treatment was delayed, and serum creatinine
was measured weekly. Treatment was resumed if calculated Ccr
increased above 50mlmin
 1; if this increase was not achieved by
day 35, the patient was taken off study. If the calculated Ccr was
50–59mlmin
 1 at any time, cisplatin was administered with the
dose of 60mgm
 2. If grade 3–4 neurotoxicity or ototoxicity
occurred, cisplatin was withheld in the subsequent cycles. If grade
3–4 nausea or vomiting was not controlled with adequate
management, cisplatin was reduced to 60mgm
 2. If grade 3–4
nonhaematologic toxicity other than alopecia and those above
mentioned, the treatment was withheld until recovery to grade 0 or
1 and the doses of epirubicin and docetaxel were reduced to 30 and
45mgm
 2, respectively, and in the patients who received
30mgm
 2 of epirubicin, docetaxel alone was reduced to
45mgm
 2. If patients required a delay of longer than 2 weeks,
they were removed from the study.
Assessment of efficacy and toxicity
At study entry, the following investigations were performed: full
history taking and physical examination, complete blood cell count
(CBC), chemistry, chest X-ray, echocardiography and computed
tomography scan. All investigations except echocardiography were
repeated before every cycle. Computed tomography scans were
performed optimally to document disease extent and to evaluate
response to treatment, every two cycles and when needed for the
confirmation of response and suspected disease progression. CBC
was repeated every week during the first cycle and the following
cycle if the patient experienced grade 4 haematologic toxicity.
Otherwise, CBC was repeated every 3 weeks.
Complete response was defined as the complete disappearance
of all clinically detectable disease for at least 4 weeks. Partial
response (PR) was defined as a more than 50% decrease in the sum
of the products of the two longest perpendicular diameters of all
measurable lesions for at least 4 weeks with no increase in size of
any area of known malignant disease and no appearance of new
areas of malignant disease. Progressive disease (PD) was defined as
a greater than 25% increase in the sum of the products of the
perpendicular diameters of all measurable lesions or the appear-
ance of any new lesion. All other outcomes were scored as stable
disease (SD).
Response rate was calculated as the ratio of number of patients
who achieved CR or PR to the number of intent-to-treat (ITT)
patients.
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lDuration of response was calculated from the first day of
treatment to the date on which PD was first observed or of the last
follow-up, for the group of responding patients. Time to
progression was calculated from the first day of treatment to the
date on which PD was first observed or of the last follow-up.
Overall survival was calculated from the first day of treatment to
the date of death or last follow-up.
Toxicity was assessed according to the National Cancer Institute
common toxicity criteria (NCI-CTC) scale version 2.0. The severity
of any toxicities not defined in the NCI-CTC were graded as
1¼mild, 2¼moderate, 3¼severe or 4¼very severe.
Statistical analysis
Descriptive statistics were reported as proportions and medians.
Kaplan–Meier estimates were used in the analysis of all time-to-
event variables, and the 95% confidence interval (CI) for the
median time to event was computed. The dose intensity (DI) was
calculated as the ratio of the total dose (expressed in milligrams)
per square metre of the patient, divided by the total treatment
duration expressed in days. In this calculation, the end of
treatment was considered to be 21 days after day 1 of the last
cycle of chemotherapy. The relative DI was calculated as the ratio
of the DI actually delivered to the DI planned by the protocol.
According to Simon’s two-stage optimal design, a sample size of
25 was required to accept the hypothesis that the true response rate
is greater than 45 with 80% power, and to reject the hypothesis that
the response rate is less than 20 with 5% significance. At the first
stage, if there were fewer than two responses out of the initial 15
patients, the study would terminate. Although the target number of
patients was 25, we planned to recruit 20% more than the target
number of patients considering drop-out.
SPSS for Windows (SPSS Inc., Chicago, IL, USA) was used for
statistical analysis.
RESULTS
Patient characteristics
From January 2002 to February 2003, 30 patients were enrolled.
The clinical characteristics of the enrolled patients are provided in
Table 1. All patients had gastric adenocarcinoma. It did not
include tumours of gastroesophageal junction. The median age was
52 years (range, 33–68), and there were 25 (83%) men and five
women. Four patients received surgery with curative intent, with a
disease-free interval of 9–32 months. Another nine patients
received palliative debulking surgery 1–2 months before the
study. The major involved organs were liver and intra-abdominal
lymph nodes.
Delivery of drug
The patients received a median of four (range, 1–8) cycles. The
average relative dose-intensity was 0.92 for epirubicin, 0.86 for
docetaxel and 0.90 for cisplatin in the patients who received
30mgm
 2 epirubicin. Dose reduction was required in eight
patients (eight cycles) and treatment was delayed in seven patients
(nine cycles) out of 22 patients who received 30mgm
 2 epirubicin.
Efficacy
All 30 patients were evaluable for response. We observed one CR,
13 PRs and 13 SDs (Table 2). The response rate was 47% (95% CI,
28–66%), and the median duration of response was 5.0 months
(95% CI, 3.0–7.0) for all responders. The median follow-up time
was 17.7 months. The median TTP was 4.1 months (95% CI, 2.4–
5.9), and the median OS was 11.0 months (95% CI, 9.5–12.4)
(Figure 1).
Toxicity
Table 3 summarises the toxicity observations. Grade 4 neutropae-
nia was observed in 16 patients (53%). The patients who received
40mgm
 2 of epirubicin (EPI-40) experienced grade 4 neutropae-
nia more frequently than those receiving 30mgm
 2 of epirubicin
(EPI-30) (88 vs 41%, P¼0.039). Febrile neutropaenia was observed
Table 1 Patient characteristics
Characteristic Number of patients
Eligible/total patients 30/30
Age (years: median (range)) 52 (33–68)
Male/female 25/5
Performance status: ECOG 0/1 3/27
Grade
Moderately differentiated 7
Poorly differentiated 21
Predominant metastatic sites
Liver 11
Lymph node 15
Peritoneum 1
Others 3
Previous treatment
Surgery with curative intent 4
Palliative surgery 9
Gastrectomy 8
Metastasectomy 2
Adjuvant chemoradiation 1
Times from chemotherapy (months)
30 20 10 0
P
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p
o
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Figure 1 Overall survival (OS) and time to progression (TTP) curve.
Table 2 Response to combination chemotherapy
Response
Total
(N¼30)
Epi 30mgm
 2
(N¼22)
Epi 40mgm
 2
(N¼8)
Complete response 1 (3%) 1 (5%) 0
Partial response 13 (43%) 9 (41%) 4 (50%)
Stable disease 13 (43%) 9 (41%) 4 (50%)
Progressive disease 3 (10%) 3 (14%) 0
Epi¼epirubicin.
Epirubicin, docetaxel and cisplatin in gastric cancer
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lmore frequently in EPI-40 than EPI-30 (75 vs 32%, P¼0.034).
Recurrent febrile neutropaenia was observed in four patients (one
in EPI-30, three in EPI-40). No treatment-related mortality was
observed.
Grade 3 nonhaematological toxicities were observed in some
patients, including nausea, vomiting, anorexia and peripheral
neuropathy. Grade 4 nonhaematological toxicity was not observed.
DISCUSSION
We report the results of combination chemotherapy with EDP in
metastatic gastric cancer patients. The response rate of 47% and
median survival of 11.0 months in this study indicate that this
regimen is active against gastric cancer and worthy of further
investigation.
The high prevalence in Korea of unresectable gastric cancer, the
poor prognosis and slow improvement of treatment outcomes
prompted us to develop a new regimen with high activity. The
addition of taxane to active drug lists enabled us to broaden the
selection of treatment options. Docetaxel in combination with
cisplatin (Roth et al, 2000; Ridwelski et al, 2001) or epirubicin
(Andre et al, 1999) showed substantial response rates as first- and
second-line chemotherapy in gastric cancer. An acceptable toxicity
profile observed from experience in transitional cell carcinoma
(Pectasides et al, 2000) encouraged us to investigate this triple
combination in gastric cancer.
We frequently encounter a response rate of 47% in the setting of
phase II studies in gastric cancer, but a median OS of 11.0 months
is a favourable result. Although selection bias in phase II
trials should be considered, median OS more than 10.0 months
is not frequently reported. The well-proven regimen ECF reported
high response rate of 71%, but median OS was 8.2 months in a
phase II trial (Findlay et al, 1994), and 8.9 months and 9.4 months
in phase III trials (Webb et al, 1997; Ross et al, 2002). An interim
analysis of a large, randomised phase III trial comparing DCF and
CF showed median OSs of 10.2 and 8.5 months, respectively (Ajani
et al, 2003).
The initial protocol with 40mgm
 2 epirubicin resulted in
an unexpectedly high incidence of grade 4 neutropaenia (seven out
of eight patients) and febrile neutropaenia (six out of eight
patients). Therefore, we decided to reduce the epirubicin dose,
and the subsequent 22 patients received 30mgm
 2 of epirubicin as
a starting dose. More patients experienced febrile neutropaenia
than those with transitional cell carcinoma who received
the similar regimen (Pectasides et al, 2000). The probable
explanation is the less frequent use of haematopoietic growth
factors in our study. In the previous study, the authors
administered 75mgm
 2 docetaxel, 40mgm
 2 epirubicin and
75mgm
 2 cisplatin, and they used prophylactic haematopoietic
growth factors with dose reduction in cases of grade 3–4
neutropaenia and/or febrile neutropaenia (Pectasides et al, 2000).
However, we only reduced the dose in the subsequent cycles,
without using prophylactic haematopoietic growth factor. We
initially planned to include the patients with moderate liver
function abnormality, that is, AST/ALT o5 times the UNL in case
of liver metastasis. We speculated whether the generous inclusion
criteria for liver function abnormality were responsible for the
increased risk of neutropaenic fever. However, in this trial, no
patients had AST/ALT 42.5 times the UNL irrespective of liver
metastasis at the enrollment. Seven patients had pretreatment
grade 1 liver function abnormality. Four (57%) out of those seven
patients experienced febrile neutropaenia and nine (39%) out of 23
patients who had normal liver function test experienced that event
(P¼0.34).
During the follow-up period, 25 patients received second-line
chemotherapy: 20 because of disease progression, and five because
of SD status after EDP. We administered salvage treatment in five
patients in the status of SD after EDP chemotherapy. We censored
these patients at the time of initiating the salvage treatment for the
calculation of TTP, and the median TTP was 4.1 months (95% CI,
2.4–5.9). We calculated again when we did not censor at that time
and rather considered as an event at the time of progression after
salvage treatment. The median TTP was 4.4 months (95% CI, 2.6–
6.3) with this calculation method.
In conclusion, combination chemotherapy with EDP is active
and relatively well tolerated in metastatic or recurrent, unresect-
able gastric cancer.
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